Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
Clinical trial NCT05509023 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05509023
- Sponsor
- Q32 Bio Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-30
- Primary completion
- 2024-12-01
- Enrollment
- 102
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.